Table 1 Patient demographics and baseline disease characteristics
Characteristic | Everolimus 10 mg/day N = 64 |
|---|---|
Age, y, median (range) | 52 (19–75) |
Sex, n (%) | Â |
   Female | 20 (31) |
   Male | 44 (69) |
Previous VEGFr-TKI therapy, n (%) | Â |
   Sunitinib | 21 (33) |
   Sorafenib | 32 (50) |
   Axitinib | 4 (6) |
   Pazopanib | 7 (11) |
All previous systemic therapy, n (%) | Â |
   Immunotherapy | 29 (45) |
   Chemotherapy | 6 (9) |
   Targeted therapy | 64 (100) |
   Other | 10 (16) |
Previous surgery, n (%) | 64 (100) |
Previous radiotherapy, n (%) | 17 (27) |
Disease sites, n (%) | Â |
   1 | 9 (14) |
   2 | 29 (45) |
   ≥3 | 26 (41) |
Common sites of metastasis, n (%) | Â |
   Lung | 52 (81) |
   Bone | 22 (34) |
   Liver | 11 (17) |
   Pleural effusion (malignant) | 11 (17) |
   Retroperitoneal mass | 9 (14) |
   Mediastinum | 8 (13) |
   Thoracic lymph nodes | 7 (11) |